The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China.
Research Group on Community Nutrition and Oxidative Stress, University of the Balearic Islands, Palma de Mallorca, Spain and CIBEROBN (Physiopathology of Obesity and Nutrition CB12/03/30038), Instituto de Salud Carlos III, Madrid, Spain.
Theranostics. 2019 Mar 16;9(7):1923-1951. doi: 10.7150/thno.30787. eCollection 2019.
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
心血管和代谢疾病（CVMD）是全球范围内主要的死亡原因，这凸显了开发新的药物治疗方法的迫切需要。小檗碱（BBR）是传统中药和阿育吠陀医学中使用超过 2000 年的重要成分。最近，BBR 因其在治疗和/或管理 CVMD 方面的药理作用而引起了广泛关注。基础、转化和临床研究的最新发现确定了 BBR 的许多新的分子靶点（如 AMPK、SIRT1、LDLR、PCSK9 和 PTP1B），并提供了新的证据支持 BBR 对抗 CVMD 的有前途的治疗潜力。因此，本综述及时概述了 BBR 在 CVMD 中的药理特性和治疗应用，并强调了最近的药理进展，这些进展验证了 BBR 作为一种有前途的治疗 CVMD 的先导药物。
